Nilotinib
|
|
|
- CAS-Nr.
- 641571-10-0
- Englisch Name:
- Nilotinib
- Synonyma:
- Tasigna;AMN 107;Nilotinib-d6;4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4 -pyridin-3-ylpyrimidin-2-yl)amino]benzamide;CS-307;Nilotinib;Nilotinibr;Nilotinib &aMp;AMN107; TASIGNA;Nilotinib, >=99%
- CBNumber:
- CB5966228
- Summenformel:
- C28H22F3N7O
- Molgewicht:
- 529.52
- MOL-Datei:
- 641571-10-0.mol
|
Nilotinib Eigenschaften
- Schmelzpunkt:
- 231-233 °C
- Dichte
- 1.36
- storage temp.
- -20°C Freezer
- Löslichkeit
- Soluble in DMSO (up to 50 mg/ml)
- Aggregatzustand
- Beige powder.
- Farbe
- Off-white
- Stabilität:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
- InChIKey
- HHZIURLSWUIHRB-UHFFFAOYSA-N
- SMILES
- N1(C=C(C)N=C1)C1C=C(C=C(C=1)NC(=O)C1C=CC(C)=C(NC2=NC=CC(C3=CC=CN=C3)=N2)C=1)C(F)(F)F
- CAS Datenbank
- 641571-10-0(CAS DataBase Reference)
Nilotinib Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Chronic myeloid leukemia (CML), a hematological stem-cell disorder, is
definitively diagnosed by the detection of the Philadelphia chromosome, a
truncated version of chromosome 22 resulting from the reciprocal translocation
of chromosomes 9 and 22 induced by a single mutagenic event. The consequence is
the juxtaposition of two genes creating a fusion gene BCR-ABL. This gene leads to
the translation of a fusion protein with increased tyrosine kinase activity that
contributes to the pathogenesis of CML. Targeting the BCR-ABL protein has led to
the successful intervention of the disease. Now established as first-line therapy for
CML, imatinib was the first selective tyrosine kinase inhibitor of BCR-ABL. Since
imatinib only binds to an inactive conformation of the ABL kinase portion, the
conformational restrictions contribute to its selectivity.
Chemische Eigenschaften
Off-White Solid
Verwenden
Nilotinib, an orally active signal transduction inhibitor
that selectively inhibits the tyrosine kinase Bcr-Abl, was
discovered and developed by Norvartis and was launched for
the treatment of chronic myeloid leukemia (CML) in patients
with Philadelphia chromosome-positive (Ph+) disease who
are resistant or intolerant to imatinib mesilate. Additional
clinical trials are currently underway for the treatment
of acute lymphoblastic leukemia (ALL) and gastrointestinal
stromal tumors (GISTs).
Definition
ChEBI: Nilotinib is a member of (trifluoromethyl)benzenes, a member of pyrimidines, a member of pyridines, a member of imidazoles, a secondary amino compound and a secondary carboxamide. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor and an anticoronaviral agent.
Allgemeine Beschreibung
Class: non-receptor tyrosine kinase
Treatment: CML
Elimination half-life = 17 h
Protein binding >97.5%
Nilotinib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Nilotinib Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 457)Lieferanten
641571-10-0()Verwandte Suche:
- Nilotinib
- Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-
- Nilotinib(TINIBS )
- 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide
- 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide
- Nilotinib & its intermediates
- Nilotinib for research
- Nilotinib(AMN 107)
- Nilotinib, AMN107, Tasigna
- TASIGNA NILOTINIB
- AMN107; TASIGNA
- 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyrimid
- Nilotinib &aMp
- 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide Nilotinib (AMN-107)
- Nilotinib 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide
- Nilotinib, >=99%
- 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyri
- CS-307
- TASIGNA;AMN-107;AMN107
- Nilotinib USP/EP/BP
- Nilotinibr
- NilotinibQ: What is
Nilotinib Q: What is the CAS Number of
Nilotinib Q: What is the storage condition of
Nilotinib
- AMN 107
- 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4 -pyridin-3-ylpyrimidin-2-yl)amino]benzamide
- Tasigna
- Nilotinib-d6
- 4-Methyl-N-[3-(4-methyl-1-imidazolyl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]benzamide
- 4-Methyl-N-[3-(4-Methyl-1H-Imidazol-1-yl)-5- (Tri?uoromethyl) Phenyl]-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino] Benzamide
- N - [3- (4-methyl-1-imidazolyl) -5-trifluoromethylphenyl] -3- [[4- (3-pyridyl) -2-pyrimidinyl] amino] -4-methylbenzamide
- 641571-10-0
- C28H22F3N7O
- AMN-107
- Cardiovascular APIs
- Inhibitors
- API
- Molecular Targeted Antineoplastic
- Nucleotides and Nucleosides
- Bases & Related Reagents
- Intermediates & Fine Chemicals
- Nucleotides
- Pharmaceuticals
- Pharmaceutical intermediate
